{"id":172096,"date":"2025-11-04T07:12:20","date_gmt":"2025-11-04T12:12:20","guid":{"rendered":"https:\/\/44.250.171.167\/?p=172096"},"modified":"2025-11-04T07:12:20","modified_gmt":"2025-11-04T12:12:20","slug":"gland-pharma-q2-fy26-earnings-results","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/gland-pharma-q2-fy26-earnings-results\/","title":{"rendered":"Gland Pharma\u00a0Q2 FY26 Earnings Results"},"content":{"rendered":"<p>Gland Pharma, a Hyderabad-based global injectable-focused pharma company, reported steady financial growth in Q2 FY26 with strong performance in key international markets.<\/p>\n<h2>Financial Highlights:<\/h2>\n<ul>\n<li>Revenues increased 5.76% year on year to \u20b91,487 crore from \u20b91,406 crore.<\/li>\n<li>Total expenses rose 6.45% to \u20b91,287 crore from \u20b91,209 crore.<\/li>\n<li>Consolidated net <a href=\"https:\/\/www.bseindia.com\/xml-data\/corpfiling\/AttachLive\/ecaea78b-a751-4978-a469-e3be6ffd5e17.pdf\" target=\"_blank\" rel=\"noopener\">profit<\/a> rose 12.2% to \u20b9184 crore from \u20b9164 crore.<\/li>\n<li>Earnings per share (EPS) improved 12.29% to \u20b911.15 from \u20b99.93.<\/li>\n<\/ul>\n<h2>Key Business Drivers:<\/h2>\n<ul>\n<li>Core business excluding European subsidiary Cenexi grew 7% in PAT with EBITDA margins steady at 35%.<\/li>\n<li>Cenexi, affected by a planned shutdown, recorded 21% revenue growth to \u20b9410 crore with infrastructure upgrades completed.<\/li>\n<li>Strong momentum expected in second half driven by new product launches and Cenexi\u2019s recovery.<\/li>\n<li>US business grew 10% YoY and Europe 16% YoY, supported by accelerated topline growth in Cenexi.<\/li>\n<li>Research &amp; Development investments increased, with seven new US molecule launches and multiple ANDA filings and approvals.<\/li>\n<\/ul>\n<h2>Outlook:<\/h2>\n<p>Management is confident about mid-teen revenue growth in FY27 supported by pipeline advancements, capacity expansion, and sustained growth across geographies. Planned capacity additions in biologics and other high-end modalities aim to strengthen future prospects.<\/p>\n<p>Gland Pharma\u2019s Q2 FY26 results reflect robust execution, margin expansion, and strategic positioning for long-term value creation.<\/p>\n<p>Explore the company\u2019s past earnings and latest concall transcripts, <a href=\"https:\/\/44.250.171.167\/symbol\/gland\/\">click here<\/a> to visit the AlphaStreet India News Channel.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter size-full wp-image-172106\" src=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/GL.png\" alt=\"Q2 FY26\" width=\"1489\" height=\"1817\" srcset=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/GL.png 1489w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/GL-246x300.png 246w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/GL-839x1024.png 839w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/GL-768x937.png 768w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/GL-1259x1536.png 1259w\" sizes=\"auto, (max-width: 1489px) 100vw, 1489px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Gland Pharma, a Hyderabad-based global injectable-focused pharma company, reported steady financial growth in Q2 FY26 with strong performance in key international markets. Financial Highlights: Revenues increased 5.76% year on year to \u20b91,487 crore from \u20b91,406 crore. Total expenses rose 6.45% to \u20b91,287 crore from \u20b91,209 crore. Consolidated net profit rose 12.2% to \u20b9184 crore from [&hellip;]<\/p>\n","protected":false},"author":1932,"featured_media":172106,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[105,392],"tags":[14452],"class_list":["post-172096","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-infographics","category-earnings","tag-pharma-company"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/GL.png","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":140762,"url":"https:\/\/alphastreet.com\/india\/gland-pharmas-acquisition-of-cenexi-decline-in-lead-products-market-share\/","url_meta":{"origin":172096,"position":0},"title":"Gland Pharma\u2019s Acquisition Of Cenexi &#038; Decline In Lead Product\u2019s Market Share","author":"Hardik Bhandare","date":"February 9, 2023","format":false,"excerpt":"Gland Pharma Limited (NSE: GLAND) is a major player in the Indian pharmaceutical market, specialising in the production and sale of generic injectable pharmaceuticals. It was founded in 1978 and went public in November 2020. The company's products are used in a wide range of therapeutic areas, including oncology, critical\u2026","rel":"","context":"In &quot;Analysis&quot;","block_context":{"text":"Analysis","link":"https:\/\/alphastreet.com\/india\/category\/stock-analysis\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/nutritional-supplement-2358477_1280-1.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/nutritional-supplement-2358477_1280-1.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/nutritional-supplement-2358477_1280-1.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/nutritional-supplement-2358477_1280-1.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/02\/nutritional-supplement-2358477_1280-1.jpg?resize=1050%2C600&ssl=1 3x"},"classes":[]},{"id":178326,"url":"https:\/\/alphastreet.com\/india\/gland-pharma-q3-fy26-earnings-results\/","url_meta":{"origin":172096,"position":1},"title":"Gland Pharma Q3 FY26 Earnings Results","author":"Divyansh_Kasana","date":"January 29, 2026","format":false,"excerpt":"Executive Summary Gland Pharma Ltd reported Q3FY26 revenues of \u20b91,695 crore, up 22.47% YoY, with consolidated net profit rising 27.32% to \u20b9261 crore. Total expenses increased 20.03% YoY to \u20b91,372 crore, reflecting strong revenue growth with controlled cost escalation. Revenue & Growth Revenues grew to \u20b91,695.00 crore in Q3FY26 from\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/GLAND.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/GLAND.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/GLAND.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/GLAND.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/GLAND.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2026\/01\/GLAND.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":172116,"url":"https:\/\/alphastreet.com\/india\/ajanta-pharma-q2-fy26-earnings-results\/","url_meta":{"origin":172096,"position":2},"title":"Ajanta Pharma\u00a0Q2 FY26 Earnings Results","author":"Divyansh_Kasana","date":"November 5, 2025","format":false,"excerpt":"Ajanta Pharma, specializing in specialty pharmaceutical manufacturing and marketing, reported a solid Q2 FY26 performance. Financial Overview: Revenues increased 14.07% to \u20b91,354 crore from \u20b91,187 crore. Total expenses rose 17.16% to \u20b91,072 crore from \u20b9915 crore. Net profit increased 20.37% to \u20b9260 crore from \u20b9216 crore. Earnings per share grew\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Q2 FY26","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/AJNT.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/AJNT.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/AJNT.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/AJNT.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/AJNT.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/AJNT.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":172164,"url":"https:\/\/alphastreet.com\/india\/aurobindo-pharma-q2-fy26-earnings-results\/","url_meta":{"origin":172096,"position":3},"title":"Aurobindo Pharma Q2 FY26 Earnings Results","author":"Divyansh_Kasana","date":"November 6, 2025","format":false,"excerpt":"Aurobindo Pharma Ltd, a leading pharmaceutical company focused on active pharmaceutical ingredients and generic pharmaceuticals, reported a steady Q2FY26 financial performance with revenues rising 6.3% year-on-year to \u20b98,286 crore. Consolidated net profit increased by 3.8% to \u20b9848 crore, reflecting resilience in key markets such as the US and Europe. Key\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Q2 FY26","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/auro.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/auro.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/auro.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/auro.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/auro.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/auro.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":170073,"url":"https:\/\/alphastreet.com\/india\/gland-pharma-q1-fy26-earnings-results\/","url_meta":{"origin":172096,"position":4},"title":"Gland Pharma Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"August 12, 2025","format":false,"excerpt":"Gland Pharma Limited, established in Hyderabad, India in 1978, has evolved from being a contract manufacturer of small-volume liquid parenteral products to becoming one of the largest and fastest-growing injectable-focused companies in the world. With a presence in over 60 countries\u2014including the United States, Europe, Canada, Australia, and India\u2014the company\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"GLAND Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/GLAND.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/GLAND.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/GLAND.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/GLAND.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/GLAND.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/GLAND.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":172155,"url":"https:\/\/alphastreet.com\/india\/sun-pharma-q2-fy26-earnings-results\/","url_meta":{"origin":172096,"position":5},"title":"Sun Pharma Q2 FY26 Earnings Results","author":"Chirag Gupta","date":"November 5, 2025","format":false,"excerpt":"Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world with trading and other incidental and related activities extending to\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Sun Pharma Q2 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Sun-Pharma-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Sun-Pharma-Q2-FY26-Earnings-Results.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Sun-Pharma-Q2-FY26-Earnings-Results.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Sun-Pharma-Q2-FY26-Earnings-Results.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Sun-Pharma-Q2-FY26-Earnings-Results.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/Sun-Pharma-Q2-FY26-Earnings-Results.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/172096","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1932"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=172096"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/172096\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/172106"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=172096"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=172096"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=172096"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}